Table 3.
Outpatient visits per LRTI and antibiotic prescription for any cause up to 150 days post-dose (intention-to-treat population)
|
Placebo group (n=786) |
Nirsevimab group (n=1564) |
Relative risk reduction (95% CI)* | |||||
|---|---|---|---|---|---|---|---|
| Number of infants with ≥1 event | Number of events | Number of events per 100 infants (95% CI) | Number of infants with ≥1 event | Number of events | Number of events per 100 infants (95% CI) | ||
| Any antibiotic prescription | 157 (20%) | 269 | 34·6 (29·0–41·2) | 258 (16%) | 409 | 26·4 (22·8–30·6) | 23·6% (3·8–39·3) |
| Outpatient visits for LRTI | 133 (17%) | 219 | 28·1 (23·5–33·8) | 171 (11%) | 253 | 16·3 (13·9–19·3) | 41·9% (25·7–54·6) |
LRTI=lower respiratory tract infection.
*
Percentage reduction in number of events per 100 infants per RSV season (5 months) in the nirsevimab group versus the placebo group.